RBF Capital LLC Trims Stock Position in CVS Health Corporation $CVS

RBF Capital LLC cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 50.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the pharmacy operator’s stock after selling 10,000 shares during the period. RBF Capital LLC’s holdings in CVS Health were worth $794,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after purchasing an additional 1,824,424 shares during the period. Capital World Investors increased its position in CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after purchasing an additional 1,419,575 shares during the period. State Street Corp increased its position in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors increased its position in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares during the period. Finally, Invesco Ltd. increased its position in CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after purchasing an additional 760,579 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insiders Place Their Bets

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Multiple articles highlight CVS as a value opportunity, with commentary that its comeback may be “just getting started” and that the stock still looks cheap relative to its earnings and growth prospects. CVS Health’s Comeback Is Just Getting Started — and Its Valuation Still Looks Shockingly Cheap
• Positive Sentiment: Analyst sentiment remains constructive: Mizuho reportedly raised its price target on CVS due to a more stable policy environment, and Morgan Stanley previously lifted its recommendation to $111 while keeping an Overweight view. Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
• Positive Sentiment: CVS continues to show operational progress, including Aetna’s AI-driven claims tools that reduced processing time by more than 20%, which could support margins and improve customer experience over time. Is CVS Health (CVS) One of Billionaire Larry Robbins’ 10 Dividend Stock Picks?
• Neutral Sentiment: Aetna also announced $130,000 in donations to Kansas City organizations, reinforcing CVS’s community-health positioning, though this is unlikely to move the stock meaningfully on its own. Aetna Donates $130,000 to Kansas City Organizations To Support Nutrition, Mental Health, Maternal Health and Health-Related Social Needs
• Neutral Sentiment: Other coverage, including Zacks and broader “CVS trending” articles, mainly reflects ongoing investor attention rather than a new fundamental catalyst. Zacks.com featured highlights include StoneCo, USANA Health, Strategic Education, Nexa Resources and CVS
• Negative Sentiment: A report on state officials revising the expense outlook for the Mass General Brigham–CVS deal may add some uncertainty around the transaction’s economics, though the market impact appears limited so far. State officials tweak expense outlook on Mass General Brigham, CVS deal

CVS Health Price Performance

Shares of NYSE:CVS opened at $100.71 on Wednesday. The business’s fifty day moving average price is $88.00 and its two-hundred day moving average price is $81.10. The stock has a market cap of $128.50 billion, a PE ratio of 44.37, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a one year low of $58.50 and a one year high of $102.77.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CVS has been the topic of several recent analyst reports. Wells Fargo & Company boosted their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Mizuho boosted their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. HSBC boosted their target price on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Tuesday, May 5th. JPMorgan Chase & Co. boosted their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Finally, Wolfe Research lowered their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.